Compare Hewlett Packard Enterprise Co (HPE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Organon & Co. Common Stock — how do they compare? Hewlett Packard Enterprise Co trades at $61 (market cap $91.34B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Hewlett Packard Enterprise Co is far larger — about 25.2× Organon & Co. Common Stock's market cap, and Hewlett Packard Enterprise Co pays the higher dividend (0.83%). Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 34 Days and Organon & Co. Common Stock for 0 Days on average.
| HPE | OGN | |
|---|---|---|
Market Cap | $91.34B | $3.62B |
Volume | 23,977,697 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $73.46 | $13.81 |
52-Week Low | $20.01 | $5.70 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $105.37B | $11.04B |
Dividend Yield | 0.83% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE stock trades at $63.17, down 10.14% today but remains near recent highs following strong AI infrastructure demand. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.11 exceeding expectations by 19%. Technical indicators show a bullish trend with support at $66 and resistance at $72. Recent news highlights a $1.2 billion AI server order from Vultr and upgraded guidance, driving positive sentiment.
HPE presents growth potential from AI infrastructure expansion and strong earnings momentum, though valuation appears elevated with a P/E of 35.47. Key risks include execution challenges in integrating Juniper Networks and competitive pressures in the server market. Analyst consensus targets $70.00 with 47.5% buy ratings, suggesting moderate upside from current levels.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
